Publicaciones en colaboración con investigadores/as de Hospital Universitario Doctor Peset (27)

2024

  1. Does the Impact of COVID-19 on Patients With Systemic Sclerosis Change Over Time?

    Arthritis Care and Research, Vol. 76, Núm. 1, pp. 88-97

2023

  1. Immunoglobulins in systemic sclerosis management. A large multicenter experience

    Autoimmunity Reviews, Vol. 22, Núm. 11

2022

  1. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis

    npj Genomic Medicine, Vol. 7, Núm. 1

2021

  1. Estimated glomerular filtration rate is a marker of mortality in the European Scleroderma Trials and Research Group (EUSTAR) database

    Rheumatology (Oxford, England), Vol. 61, Núm. 1, pp. 213-222

2020

  1. A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept

    PLoS ONE, Vol. 14, Núm. 2

  2. GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways

    Nature Communications, Vol. 10, Núm. 1

  3. Identification of a 3′-Untranslated Genetic Variant of RARB Associated With Carotid Intima-Media Thickness in Rheumatoid Arthritis: A Genome-Wide Association Study

    Arthritis and Rheumatology, Vol. 71, Núm. 3, pp. 351-360

  4. LAUDES Study: impact of digital ulcers on hand functional limitation, work productivity and daily activities, in systemic sclerosis patients

    Rheumatology International, Vol. 39, Núm. 11, pp. 1875-1882

  5. Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: A European Scleroderma Trials and Research (EUSTAR) analysis

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 9, pp. 1242-1248

  6. Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the european scleroderma trials and research (eustar) cohort

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 5, pp. 648-656

  7. Pure Membranous Lupus Nephritis: Description of a Cohort of 150 Patients and Review of the Literature

    Reumatologia Clinica, Vol. 15, Núm. 1, pp. 34-42

2018

  1. Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study

    Arthritis and Rheumatology, Vol. 70, Núm. 11, pp. 1829-1834

  2. Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis

    PLoS ONE, Vol. 13, Núm. 5

2017

  1. Influence of coronary artery disease and subclinical atherosclerosis related polymorphisms on the risk of atherosclerosis in rheumatoid arthritis

    Scientific Reports, Vol. 7

  2. Update of EULAR recommendations for the treatment of systemic sclerosis

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 8, pp. 1327-1339

2016

  1. Brief Report: IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies

    Arthritis and Rheumatology, Vol. 68, Núm. 9, pp. 2338-2344

  2. Influence of elevated-CRP level-related polymorphisms in non-rheumatic Caucasians on the risk of subclinical atherosclerosis and cardiovascular disease in rheumatoid arthritis

    Scientific Reports, Vol. 6

  3. Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis

    Pharmacogenomics Journal, Vol. 16, Núm. 2, pp. 137-140

2015

  1. A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study

    Microvascular Research, Vol. 102, pp. 19-24